

1.

Dear PSG investigator,

In the midst of the current COVID-19 pandemic, the PSG seeks feedback from member investigators to determine its implications in clinical practice and research, namely the uptake of technology enabled clinical care and research.

The survey has two modules covering, respectively, clinical care and research

For purposes of this survey, face-to-face refers to the traditional evaluation which allows for a complete physical examination. Non face-to-face refers to all other forms of evaluation including telephone, synchronous and asynchronous video conferencing, wearable devices, remote monitoring and limited in home data collection (e.g. blood draw) by a trained local coordinator.


Please do not use your browser's back and forward button to navigate. Only use the 'Prev' and 'Next' buttons at the bottom of the page.



2. CLINICAL CARE MODULE

BEFORE COVID-19

1. Select the modalities of non face-to-face patient-physician communication below that you used before COVID-19 to provide care to PD patients in replacement of a face-to-face clinic visit and rank them by use. The most used modality is ranked 1. If a modality was not used, please select N/A:



	elephone	
E-	-mail or other forms of secure messaging	
Vi	ideo conference	
No	ot applicable	
o	ther (please specify)	



3. CLINICAL CARE MODULE

DURING COVID-19

1. Select the modalities of non face-to-face patient-physician communication below that you **NOW** use to provide care to PD patients in replacement of an face-to-face clinic visit and rank them by use. The most used modality is ranked 1. If a modality is not used, please select N/A:

modality is fatiked 1. If a modality is not used, please select NA.	
•	
Telephone	
□ N/A	
	Þ
•	
E-mail or other forms of secure messaging	
□ N/A	
•	Þ
•	
Video conference	
□ N/A	
	1-1
	▶
	<u>.</u> •
	<u>.</u>
•	<u> </u>
Other {Please enter response in Q2 below}	<u> </u>
•	
Other {Please enter response in Q2 below}	<u> </u>
Other {Please enter response in Q2 below} □ N/A	
Other {Please enter response in Q2 below}	
Other {Please enter response in Q2 below} □ N/A	
Other {Please enter response in Q2 below} □ N/A	
Other {Please enter response in Q2 below} □ N/A	
Other {Please enter response in Q2 below} □ N/A	
Other {Please enter response in Q2 below} □ N/A	
Other {Please enter response in Q2 below} □ N/A	
Other {Please enter response in Q2 below} □ N/A	

3. Which modalities of non face-to-face patient-physician communication below are NOW reimbu	rsed for
patient care? (select all options that apply)	
Telephone	
E-mail or other forms of secure messaging	
Video conference	
Not applicable	
Other (please specify)	
4. What type of platform have you used to conduct telemedicine (synchronous video conferencing	g) clinical
visits? (select all options that apply)	
Institution mandated video-conference system	
Commercial video-conference system of your choice	
Smartphone video call	
Social media video call (e.g. Whatsapp, Facebook)	
□ N/A	
Other (please specify)	

	hat platform have you used for telemedicine (synchronous video conferencing) (select all options that
appl	y) Zoom
	Vidyo
	Doxy.me
	Doximity
	BlueJeans CRD Health A 6 due
	SBR Health/Vidyo
	V2MD by Medisprout
	Medweb
	Polycom
	WhatsApp
	Skype for business
	Cisco Jabber
	In Touch Health
	Univago
	Coviu
	American Well
	Microsoft Teams
	Google Meets
	Facebook platform
	N/A
	Other (please specify)

	1st choice	2nd c	hoice	3rd choice
nstitutional preference	\bigcirc			
IIPAA consideration	\bigcirc			
atient preference				0
rovider preference				
ntegration with existing lectronic health records	\circ			
I/A				
other (please specify)				
ner (please specify)				
		1st choice	2nd choice	3rd choice
rouidor rociotopoo				
		0	0	0
atient resistance		0	0	0
atient resistance ack of access for provider	of software, camera	0	0	0
atient resistance ack of access for provider ack of access for patient (lack o	of software, camera	OOOO	O O O	0
atient resistance ack of access for provider ack of access for patient (lack or internet)			OOOOO	0 0 0
atient resistance ack of access for provider ack of access for patient (lack or internet) astitutional or practice reluctance			0	
ratient resistance ack of access for provider ack of access for patient (lack or internet) Institutional or practice reluctance				
Provider resistance Patient resistance ack of access for provider ack of access for patient (lack of rinternet) Institutional or practice reluctance I/A Other (please specify) Iner (please specify)				
Patient resistance ack of access for provider ack of access for patient (lack or internet) Institutional or practice reluctance I/A Other (please specify)				
Patient resistance ack of access for provider ack of access for patient (lack or internet) Institutional or practice reluctance I/A Other (please specify) Internet (please specify)	e to adopt			
ack of access for provider ack of access for patient (lack or internet) astitutional or practice reluctance WA Other (please specify) her (please specify) 8. For PD-related proces	e to adopt lure visits (such as E	•	•	•
atient resistance ack of access for provider ack of access for patient (lack of internet) astitutional or practice reluctance //A other (please specify) ner (please specify) 8. For PD-related proced Levodopa/Carbidopa ent	e to adopt dure visits (such as E teric infusion therapy	•	•	•
atient resistance ack of access for provider ack of access for patient (lack of internet) astitutional or practice reluctance //A other (please specify) ner (please specify) 8. For PD-related proced Levodopa/Carbidopa ent	e to adopt dure visits (such as E teric infusion therapy d BEFORE COVID 19	y), did you: (select a	all options that apply	•
atient resistance ack of access for provider ack of access for patient (lack of internet) astitutional or practice reluctance //A other (please specify) ner (please specify) 8. For PD-related procect Levodopa/Carbidopa ent Conduct visit as planne Perform remote assess	e to adopt dure visits (such as E teric infusion therapy	y), did you: (select a	all options that apply	•
ack of access for provider ack of access for patient (lack or internet) Institutional or practice reluctance I/A Other (please specify) The results of access for patient (lack or internet) The results of access for patient (lack or internet) The results of access for provider The results of access for patient (lack of ac	e to adopt dure visits (such as E teric infusion therapy d BEFORE COVID 19	y), did you: (select a	all options that apply	•

Greater use of other non face-to-face modalities such as wearables devices No change Other (please specify)	apply)	Greater uptake of telemedicine (synchronous video conferencing) and fewer in-person visits	
No change			
Other (please specify)			
		Other (please specify)	




CLINICAL RESEAF	RCH MODULE			
Are you actively inv Yes	olved in clinical res	search		
No				



5. CLINICAL RESEARCH MODULE

BEFORE COVID-19

1. Rank the modalities of non face-to-face subject-investigator communication below that you were using for scheduled clinical research visits. The most used modality is ranked 1. If a modality was not used, please select N/A.






6. CLINICAL RESEARCH MODULE

٠.		· • · ·			 •	•	_ `
ы	IDING	2	\/ID	10			

DURING COVID-19
1. What proportion of your research activities was suspended?
75 - 100%
50 - 74%
< 50%
None was suspended
2. If receased activity was avapanded what were the implicatione? (calcut all entions that apply)
2. If research activity was suspended, what were the implications? (select all options that apply)
Furlough or lay-off research staff such as coordinators, finance managers
Closure of the clinical research unit
Suspend participant recruitment to studies
Suspend start-up of new studies
N/A
Other (please specify)
3. If you were able to convert scheduled face-to-face clinical research assessments visits to a non face-to-face
format, which modality did you use. Select and rank the applicable options. The most common modality is
ranked 1. If a modality was not used, please select N/A.
\$
Telephone
□ N/A
_
\$
E-mail or other forms of secure messaging
□ N/A



		n file			
Cile muste	from sponsor and note to	o ille			
	ocol deviation	LIDD and absolved it has		alda siidikkala asaa aali	
		al IRB and obtained it bef	ore doing the telene	aith visit/phone cail	
Ш.	RB modification				
	ent and caregiver to the I				
	f to use new technology p	properly			
Not applic					
Other (ple	ease specify)				
. If research	visits needed proce	edures, did you: (sele	ect all options tha	at apply)	
See patie	nt and perform procedure	e as planned			
Perform re	emote assessments and	defer procedure			
Cancel vis	sit entirely				
Not applic	cable				
Other (ple	ease specify)				
-		ace-to-face visits in re	eplacement of re	egular face-to-face re	esearch visits,
useful were	these visits in your	research:			
-			eplacement of re	egular face-to-face re	esearch visits,



7. DEMOGRAPHICS AND CLINICAL/RESEARCH PRACTICE

1. Age group		
Under 31		
31 - 40		
41 - 50		
51 - 60		
> 60		
2. Years of clinical	practice	
< 6		
6 - 10		
11 - 15		
> 15		
3. Years of clinical	research	
< 6		
6 - 10		
11 - 15		
> 15		
1. Please, describe yo L00%)	our practice: (indicate the % of dedicated time for each component bel	ow for a total of
Clinical		
Research		
Administrative		
Feaching Feaching		
Other		